GoHealth Gestione
Criteri Gestione verificati 1/4
GoHealth Il CEO è Vijay Kotte, nominato in Jun2022, e ha un mandato di 3.92 anni. la retribuzione annua totale è $ 13.76M, composta da 7% di stipendio e 93% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 5.69% delle azioni della società, per un valore di $ 1.04M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.1 anni e 0.8 anni.
Informazioni chiave
Vijay Kotte
Amministratore delegato
US$13.8m
Compenso totale
| Percentuale dello stipendio del CEO | 7.05% |
| Mandato del CEO | 3.9yrs |
| Proprietà del CEO | 5.7% |
| Durata media del management | 3.1yrs |
| Durata media del Consiglio di amministrazione | less than a year |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento della narrazione • Apr 30
GOCO: Lower P E And Improved Revenue Outlook Will Support Returns
Analysts have cut their 12 month price target for GoHealth by about $3, reflecting a reset in fair value assumptions along with updated views on revenue growth, margins and future P/E, following a recent downgrade highlighted in Street research. Analyst Commentary Bearish analysts are framing the latest downgrade as part of a broader reset in expectations for GoHealth, with the lower 12 month price target seen as a response to questions about how quickly the business can translate its model into consistent, scalable earnings.
Aggiornamento della narrazione • Apr 14
GOCO: Lower Earnings Multiple Will Support Upside Despite Nasdaq Compliance Risk
Analysts cut their GoHealth price target from $7.70 to $4.70 as they factor in updated assumptions for revenue growth and margins, and incorporate the recent downgrade at Freedom Broker into their outlook. Analyst Commentary Bullish Takeaways Bullish analysts view the reset to a US$4.70 target as a cleaner entry point that better reflects current expectations for revenue growth and margins, which they see as more achievable under updated assumptions.Aggiornamento della narrazione • Mar 31
GOCO: Discount Rate Tweaks Will Support Upside Despite Nasdaq Compliance Risk
Analysts have nudged up their price target on GoHealth to $7.70, citing a slightly lower discount rate and modest tweaks to long term revenue growth, profit margin, and future P/E assumptions as key drivers of the change. What's in the News On March 18, 2026, GoHealth received a notice from Nasdaq that it is not in compliance with the minimum US$35 million market value of listed securities requirement under Listing Rule 5550(b)(2) (Nasdaq filing).Aggiornamento della narrazione • Mar 17
GOCO: Stable Assumptions And Low Future P E Will Support Returns
Analysts have kept their GoHealth price target unchanged at $4.50. They point to only slight tweaks in revenue growth, profit margin and forward P/E assumptions that do not materially alter their overall view of the stock.Aggiornamento della narrazione • Mar 03
GOCO: Stronger Margins And Lower P E Will Support Future Cash Flow
Analysts have trimmed their price target on GoHealth to reflect slightly weaker revenue expectations, a modestly stronger profit margin, and a marginally lower forward P/E. This results in a small downward adjustment in their $ price outlook for the stock.Aggiornamento della narrazione • Feb 17
GOCO: Carrier Relationship Reset Will Support Future Cash Flow Recovery
Analysts have sharply reduced GoHealth's target, with one firm lowering its price target to $5 from $12 after Q3 results came in below expectations because of topline weakness tied to a suspended relationship with a large carrier. Analyst Commentary Bearish analysts are recalibrating their expectations after Q3 results came in well below what they were looking for, and the cut in the price target to $5 from $12 signals a more cautious stance on the stock.Aggiornamento della narrazione • Feb 03
GOCO: Cash Burn Discipline And Carrier Reset Could Support Future Upside
Analysts have cut their price targets on GoHealth, including a reduction to US$5 from US$12. They cited weaker than expected Q3 results tied to topline softness from a suspended carrier relationship, a pullback in new enrollment growth, and ongoing concerns about market headwinds and cash flow sustainability.Aggiornamento della narrazione • Jan 20
GOCO: Cash Discipline And Carrier Reset Will Support Future Cash Flow
Analysts have sharply reduced their GoHealth price targets, with one moving from US$12 to US$5. This reflects weaker Q3 results tied to a suspended carrier relationship, as well as concerns about ongoing market headwinds and cash flow visibility.Aggiornamento della narrazione • Jan 06
GOCO: Focus On Cash Burn Discipline And Carrier Reset Supporting Future Stability
Narrative Update on GoHealth Analysts have cut their 12 month price target for GoHealth to US$5.00 from US$12.00, reflecting weaker Q3 results tied to a suspended relationship with a large carrier, softer revenue and Medicare submissions, a pullback in new enrollment growth, and concerns around ongoing market headwinds and uncertainty about achieving sustainable positive cash flow. Analyst Commentary Recent research updates on GoHealth reflect a cautious reset of expectations following Q3 results that came in below prior estimates, with price targets and ratings adjusted to reflect execution risks and a more uncertain growth outlook.Aggiornamento della narrazione • Dec 15
GOCO: Cash Flow Improvements Will Outweigh Carrier Loss And Enrollment Pullback
Analysts have sharply reduced their price target on GoHealth from approximately $12.00 to about $5.00 per share. This reflects weaker than expected Q3 results, revenue headwinds from a suspended carrier relationship, and persistent concerns about the company's ability to deliver sustainable growth and cash flow in a challenging market.Aggiornamento della narrazione • Dec 01
GOCO: Focus On Profitability And Cash Burn Reduction Will Drive Future Stability
Analysts have sharply reduced GoHealth's fair value estimate from $14 to $7.70 per share. They cite ongoing market headwinds, weaker-than-expected Q3 results, and challenges in revenue growth as key reasons for the downward revision.Aggiornamento della narrazione • Nov 17
GOCO: Recent Credit Move Will Boost Flexibility Ahead of Enrollment Period
Analysts have revised GoHealth's fair value estimate downward from $17.20 to $14.00. This change is due to updated model assumptions and increased caution surrounding revenue growth following recent company results and financial transactions.Aggiornamento della narrazione • Aug 25
Financial Flexibility And M&A Will Unlock Medicare And Senior Health Potential
GoHealth’s price target has been revised downward to $18.40, primarily reflecting reduced expectations for both future earnings multiples and revenue growth. What's in the News GoHealth has formed a Transformation Committee with new board members to evaluate strategic opportunities, including acquisitions, securitizations, and capital structure options.Aggiornamento della narrazione • Aug 10
Financial Flexibility And M&A Will Unlock Medicare And Senior Health Potential
Despite higher revenue growth forecasts, GoHealth’s future P/E multiple has dropped sharply, indicating reduced investor confidence in earnings quality or sustainability, leading to a lower consensus price target of $19.60. What's in the News GoHealth has formed a Transformation Committee to evaluate acquisitions, financial structure options, securitizations, and other strategic opportunities for value creation.
Nuova narrazione • Mar 31
Medicare Engagement And Efficiency Will Drive Future Savings
GoHealth's shift to Medicare engagement enhances consumer relations and boosts operational efficiency, lowering costs and improving margins.Seeking Alpha • May 28
GoHealth: Turning The Corner On Operating Cash Flow
Summary GoHealth's shares have continued to drop despite positive developments, presenting an opportunity for investors to build a position over time. The company has shown positive operating cash flow for five consecutive quarters, reflecting a shift towards profitability and cost containment. Although GOCO previously needed to rely on debt funding, it is now deleveraging, and its focus on operating cash flow is a positive sign for investors. Read the full article on Seeking AlphaArticolo di analisi • May 10
GoHealth, Inc. (NASDAQ:GOCO) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Shareholders will be ecstatic, with their stake up 44% over the past week following GoHealth, Inc. 's ( NASDAQ:GOCO...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$294m |
| Dec 31 2025 | US$14m | US$969k | -US$261m |
| Sep 30 2025 | n/a | n/a | -US$203m |
| Jun 30 2025 | n/a | n/a | -US$30m |
| Mar 31 2025 | n/a | n/a | -US$2m |
| Dec 31 2024 | US$6m | US$900k | -US$7m |
| Sep 30 2024 | n/a | n/a | -US$33m |
| Jun 30 2024 | n/a | n/a | -US$64m |
| Mar 31 2024 | n/a | n/a | -US$67m |
| Dec 31 2023 | US$5m | US$900k | -US$67m |
| Sep 30 2023 | n/a | n/a | -US$127m |
| Jun 30 2023 | n/a | n/a | -US$132m |
| Mar 31 2023 | n/a | n/a | -US$146m |
| Dec 31 2022 | US$10m | US$485k | -US$150m |
Compensazione vs Mercato: La retribuzione totale di Vijay ($USD 13.76M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 638.05K ).
Compensazione vs guadagni: La retribuzione di Vijay è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Vijay Kotte (47 yo)
3.9yrs
Mandato
US$13,757,255
Compensazione
Mr. Vijay Kumar Kotte serves as Chief Executive Officer & Director of GoHealth, Inc. from June 06, 2022. He served as Executive Vice President, Strategy & Corporate Development and Chief Solutions Officer...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder & Non-Executive Co-Chairman | 6.3yrs | US$150.00k | 0.042% $ 7.6k | |
| Co-Founder & Non-Executive Co-Chairman | 6.3yrs | US$150.00k | 0.11% $ 20.7k | |
| CEO & Director | 3.9yrs | US$13.76m | 5.69% $ 1.0m | |
| Chief Financial Officer | 1.6yrs | US$2.06m | 0.42% $ 77.6k | |
| Chief Operating Officer | 2.8yrs | US$2.19m | 1.25% $ 229.0k | |
| Chief Technology Officer | 1.5yrs | Nessun dato | Nessun dato | |
| Vice President of Investor Relations | no data | Nessun dato | Nessun dato | |
| Chief Legal Officer & Corporate Secretary | 2.3yrs | Nessun dato | 0.14% $ 26.1k | |
| Chief Marketing Officer | 3.3yrs | Nessun dato | Nessun dato | |
| Chief People Officer | 3.3yrs | Nessun dato | Nessun dato | |
| Chief Distribution Officer | 1.3yrs | Nessun dato | Nessun dato |
3.1yrs
Durata media
47yo
Età media
Gestione esperta: Il team dirigenziale di GOCO è considerato esperto (durata media dell'incarico 3.1 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder & Non-Executive Co-Chairman | 6.3yrs | US$150.00k | 0.042% $ 7.6k | |
| Co-Founder & Non-Executive Co-Chairman | 6.3yrs | US$150.00k | 0.11% $ 20.7k | |
| CEO & Director | 3.9yrs | US$13.76m | 5.69% $ 1.0m | |
| Independent Director | 4yrs | US$150.00k | 0.58% $ 105.8k | |
| Director | less than a year | US$135.48k | Nessun dato | |
| Director | less than a year | Nessun dato | Nessun dato | |
| Director | less than a year | US$262.74k | Nessun dato | |
| Director | less than a year | US$262.74k | Nessun dato | |
| Director | less than a year | US$262.74k | Nessun dato |
0.8yrs
Durata media
55yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di GOCO non è considerato esperto (durata media del mandato 0.8 anni), il che suggerisce un nuovo consiglio.
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/21 06:46 |
| Prezzo dell'azione a fine giornata | 2026/05/21 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
GoHealth, Inc. è coperta da 16 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Steven Valiquette | Barclays |
| Steven Valiquette | Barclays |
| Michael Cherny | BofA Global Research |